Thomas N. Wight

Active 1975–2024

141
Papers
25,023
Citations
97
h-index
141
i10-index

Citations

Citations per year for Thomas N. Wight1975: 2 citations1976: 4 citations1977: 2 citations1978: 2 citations1979: 8 citations1980: 5 citations1981: 10 citations1982: 13 citations1983: 14 citations1984: 38 citations1985: 41 citations1986: 32 citations1987: 28 citations1988: 23 citations1989: 29 citations1990: 31 citations1991: 43 citations1992: 57 citations1993: 70 citations1994: 94 citations1995: 68 citations1996: 78 citations1997: 106 citations1998: 115 citations1999: 139 citations2000: 161 citations2001: 148 citations2002: 190 citations2003: 160 citations2004: 257 citations2005: 201 citations2006: 189 citations2007: 220 citations2008: 220 citations2009: 208 citations2010: 203 citations2011: 246 citations2012: 222 citations2013: 210 citations2014: 289 citations2015: 229 citations2016: 220 citations2017: 158 citations2018: 312 citations2019: 602 citations2020: 778 citations2021: 685 citations2022: 507 citations2023: 345 citations2024: 528 citations2025: 255 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,994 citing papers, 33.9% of this breakdownChina: 694 citing papers, 7.9% of this breakdownUnited Kingdom: 624 citing papers, 7.1% of this breakdownGermany: 426 citing papers, 4.8% of this breakdownCanada: 359 citing papers, 4.1% of this breakdownJapan: 316 citing papers, 3.6% of this breakdownItaly: 309 citing papers, 3.5% of this breakdownFrance: 276 citing papers, 3.1% of this breakdownAustralia: 271 citing papers, 3.1% of this breakdownSweden: 223 citing papers, 2.5% of this breakdownNetherlands: 220 citing papers, 2.5% of this breakdownSpain: 198 citing papers, 2.2% of this breakdown
0%33.9%Other 21.7%

Fields

  • Biochemistry, Genetics and Molecular Biology40.8%
  • Medicine40.4%
  • Immunology and Microbiology6.8%
  • Materials Science5%
  • Engineering2.6%
  • Neuroscience1.8%
  • Other2.6%

Topics

  • Proteoglycans and glycosaminoglycans research7.4%
  • Cell Adhesion Molecules Research3.8%
  • Glycosylation and Glycoproteins Research3.3%
  • Protease and Inhibitor Mechanisms3.2%
  • Tissue Engineering and Regenerative Medicine2.5%
  • Electrospun Nanofibers in Biomedical Applications2.3%
  • Other77.5%

Coauthors

All papers

Open in search
  1. Exuberant fibroblast activity compromises lung function via ADAMTS4

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gwenn E. McLaughlin, Matthew L. Paden, Keiko M. Tarquinio, Bria M. Coates, Neethi Pinto, Juliane Bubeck Wardenburg, Adrienne G. Randolph, Anna A. Agan, Tanya Novak, Margaret M. Newhams, Stephen C. Kurachek, Mary E. Hartman, Allan Doctor, Edward J. Truemper, Sidharth Mahapatra, Kate G. Ackerman, L. Eugene Daugherty, Mark W. Hall, Neal J. Thomas, Scott L. Weiss, Julie C. Fitzgerald, Renee A. Higgerson, Laura L. Loftis, Rainer Gedeit, Marc-André Dugas, Thomas N. Wight, Stacey Schultz‐Cherry, Stephania A. Cormier, Kathryn Shaw‐Saliba, Andrew Pekosz, Richard E. Rothman, Kuan‐Fu Chen, Zifeng Yang, Richard J. Webby, Nanshan Zhong, Jeremy Chase Crawford, Paul G. Thomas - Nature 2020 cited by 226

  2. Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation

    Authors: , , , , , , , - Frontiers in Immunology 2020 cited by 265

  3. Human tissue-engineered blood vessels for adult arterial revascularization

    Authors: , , , , , , , , , , , - Nature Medicine 2006 cited by 1,068

  4. The extracellular matrix: an active or passive player in fibrosis?

    Authors: , - American Journal of Physiology-Gastrointestinal and Liver Physiology 2011 cited by 656

  5. Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy

    Authors: , , , , - Pharmacological Reviews 2009 cited by 549

  6. Cardiovascular Pathology in Hutchinson-Gilford Progeria: Correlation With the Vascular Pathology of Aging

    Authors: , , , , , , , , , , , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2010 cited by 426

  7. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation

    Authors: , , , , - Immunologic Research 2014 cited by 194

  8. A role for proteoglycans in vascular disease

    Authors: - Matrix Biology 2018 cited by 156

  9. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1

    Authors: , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 308

  10. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans

    Authors: , , - Cardiovascular Research 2008 cited by 295

  11. Early Human Atherosclerosis

    Authors: , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2007 cited by 431

  12. Provisional matrix: A role for versican and hyaluronan

    Authors: - Matrix Biology 2016 cited by 223

  13. Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: A pathology study

    Authors: , , , , , , , , , , , - Atherosclerosis 2015 cited by 194

  14. Pivotal role for decorin in angiogenesis

    Authors: , , - Matrix Biology 2015 cited by 180

  15. Versican promotes T helper 17 cytotoxic inflammation and impedes oligodendrocyte precursor cell remyelination

    Authors: , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 52

  16. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson–Gilford progeria syndrome

    Authors: , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 294

  17. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.

    Authors: , , , , , - Journal of Clinical Investigation 1998 cited by 315

  18. 4-Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer

    Authors: , , , , , , - Frontiers in Immunology 2015 cited by 290

  19. Versican and the control of inflammation

    Authors: , , - Matrix Biology 2014 cited by 215

  20. Differential Accumulation of Proteoglycans and Hyaluronan in Culprit Lesions

    Authors: , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2002 cited by 281

  21. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells

    Authors: , , , , , - Journal of Leukocyte Biology 2009 cited by 149

  22. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan

    Authors: , , , , , , - Journal of Lipid Research 2002 cited by 116

  23. Formation of Hyaluronan- and Versican-Rich Pericellular Matrix Is Required for Proliferation and Migration of Vascular Smooth Muscle Cells

    Authors: , , - Arteriosclerosis Thrombosis and Vascular Biology 1999 cited by 487

  24. CD44 Costimulation Promotes FoxP3+ Regulatory T Cell Persistence and Function via Production of IL-2, IL-10, and TGF-β

    Authors: , , , , , , , , , - The Journal of Immunology 2009 cited by 161